Ferramentas Pessoais
Você está aqui: Entrada Notícias Lorena Diéguez

Lorena Diéguez

HCP_EIS2019_LDieguez.png

 

 

 
Lorena Diéguez
CEO, RUBYnanomed; Medical Devices Group Leader, INL

ABOUT THE SPEAKER:

Lorena Diéguez joined INL in 2014 as Staff Researcher and is, since May 2018, the leader of the Medical Devices research group. Her research is focused in the development of biomicrofluidic devices mainly devoted to Translational Medical Research in close collaboration with Hospitals. For that purpose, her work is devoted to the development of integrated biosensing systems and nanobioengineered diagnostics microsystems for the isolation and characterization of Tumor Cells from body fluids of cancer patients, as well as the development of microfluidic organ-on-a-chip 3D models. Lorena is also very interested in translating her technology from the lab to the clinic, and she has been very active in her endeavours as entrepreneur, creating the spin-off company RUBYnanomed in the field of liquid biopsy. She obtained her Bachelor's degree in Physics and her Masters in Optoelectronics at the University of Santiago de Compostela in 2005, then completed her Masters in Nanoscience and Nanotechnology at the University of Barcelona (UB) in 2007 and obtained her PhD in Nanosciences in optical and electrochemical biosensors at the Institute for Bioengineering of Catalonia and the ETH Zürich. Her postdoctoral research at the University of South Australia (UniSA) from 2010 was devoted to the study of rare cells from biological samples using microfluidics.

 

ABOUT THE PRESENTATION:

"RUBYnanomed: non-invasive monitoring of cancer progression"

Cancer metastasis is responsible of 90% of cancer related deaths. To find metastasis early, there is an obvious need for continuous cancer progression monitoring, but current tools used in the clinic (tissue biopsy and imaging technologies) are not able to be performed regularly on the metastatic site and often miss early spreading. RUBYnanomed is a spin-off company from INL that offers access to cancer material as the disease progresses in a non-invasive way.

 

[back to the programme]